Tasly Pharmaceutical Group Co Ltd
SSE:600535
Gross Margin
Tasly Pharmaceutical Group Co Ltd
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| CN |
|
Tasly Pharmaceutical Group Co Ltd
SSE:600535
|
22.2B CNY |
67%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
831.3B USD |
81%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
56%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
373.9B USD |
68%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.8T DKK |
85%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
210.9B CHF |
74%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
189.1B CHF |
75%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
163.2B GBP |
82%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
210.3B USD |
79%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
163.5B USD |
68%
|
|
| FR |
|
Sanofi SA
PAR:SAN
|
116.7B EUR |
70%
|
Tasly Pharmaceutical Group Co Ltd
Glance View
In the heart of China's bustling pharmaceutical landscape lies Tasly Pharmaceutical Group Co Ltd, a company intricately blending traditional herbal wisdom with cutting-edge scientific innovation. Founded in 1994, this enterprise has carved a niche in the competitive world of healthcare by focusing on Traditional Chinese Medicine (TCM) while also expanding into chemical medicine and biological drugs. Tasly's ecosystem thrives on the research, development, manufacturing, and marketing of its diverse product portfolio, which includes patent medicines, herbal injections, and health supplements. The crown jewel in its product lineup is the Compound Danshen Dripping Pill, a herbal medicine aimed at cardiovascular ailments, a testament to the company's commitment to merging ancient remedies with modern health solutions. By establishing an extensive distribution network both domestically and internationally, Tasly ensures its unique offerings reach a wide audience, catering not only to China's growing appetite for health products but also tapping into global markets hungry for alternative medicine solutions. Tasly’s financial engine leverages its broad spectrum of offerings, driven by both consumer demand for TCM and the pharmaceutical industry's appetite for innovation. The company invests significantly in research and development, with a particular emphasis on internationalizing TCM and obtaining global recognition for its products through clinical trials and partnerships. Such strategic actions bolster its competitive edge, positioning Tasly as a leader in an industry where tradition and science converge. Revenue streams are further diversified by the company's health management services and a growing footprint in biotechnology, showcasing its adaptability and forward-thinking approach. This intricate ballet of innovation and tradition enables Tasly Pharmaceutical Group to not just survive but thrive in an industry characterized by rapid advancements and shifting consumer paradigms.
See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on Tasly Pharmaceutical Group Co Ltd's most recent financial statements, the company has Gross Margin of 66.9%.
You don't have any saved screeners yet